The US Food and Drug Administration (FDA) has granted 510(k) clearance to 4DMedical’s non-contrast, computed tomography (CT)-based ventilation-perfusion imaging technology, CT:VQ, for respiratory ...
In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion. MELBOURNE, Australia, March 30, ...
Educating physicians about ventilation-perfusion scanning as an alternative to CT for the diagnosis of pulmonary embolisms led to a 23 percent decrease in patient exposure, according to a study ...
4DMedical Limited has unveiled its innovative CT:VQ technology at RSNA 2024, offering a revolutionary alternative to traditional Nuclear VQ scans. This new imaging solution promises faster, safer, and ...
LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- 4DMedical, a leader in advanced respiratory imaging, today announces U.S. Food and Drug Administration (FDA) 510(k) clearance for CT:VQ™, the world's first ...
Hi, everyone. Thank you so much for joining us today and for your interest in 4DMedical and today's investor presentation. Of course, the key focus of today's presentation is going to be CT:VQ post ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results